C-2KLQMitoRx Therapeutics
mitochondrial metabolism, small molecule, obesity
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-2KLQ
C-2KLQC-2KLQmitochondrial metabolism, small molecule, obesity
0-100 chain-logic scale · 15 dimensions · scored on public evidence
MitoRx Therapeutics mitochondrial metabolism, small molecule, obesity
MitoRx is a biotech company targeting the restoration of healthy mitochondrial metabolism in high-risk obesity. Its lead asset, MTRX31, is a first-in-class small molecule designed to rebalance carbohydrate and fat oxidation, eliminate ectopic fat, preserve lean mass, and improve insulin sensitivity. The company says it was spun out of the University of Exeter in 2021 and is headquartered in Harwell Oxford, with research operations in Cambridge.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
MitoRx Therapeutics — Early mechanism · Lower middle. Derived deterministically from 1 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic